) recently announced that the US Food and Drug Administration
(FDA) has approved the company's marketed product, Vibativ
(telavancin), for an additional indication.
The FDA approved Vibativ for treating adults suffering from
hospital-acquired and ventilator-associated bacterial pneumonia.
The disease is also known as nosocomial pneumonia (NP). Approval
was gained for treating the disease caused by susceptible
isolates of staphylococcus aureus in the absence of suitable
Following the approval, Theravance intends to launch the drug
for the new indication in the third quarter of 2013. The FDA
approved Vibativ for the new indication on the basis of data from
two phase III studies (ATTAIN I and II).
We note that Vibativ is already approved in the US for treating
adults with complicated skin and skin structure infections
(cSSSI) caused by susceptible isolates of gram-positive bacteria,
including both methicillin-resistant and methicillin-susceptible
strains of staphylococcus aureus. Vibativ is also marketed in
Canada for cSSSI.
In Nov 2012, an advisory panel of FDA issued a 13-2 favorable
vote about the safety and efficacy of the drug for the NP
indication due to susceptible isolates of gram-positive
microorganisms in the absence of suitable alternatives. The panel
did not recommend the drug as a first-line treatment for NP. The
FDA approval was also for the limited indication.
We believe that the label expansion of the drug for a limited
indication will restrict the drug's sales potential.
Consequently, we do not expect the FDA decision to boost
Theravance's top line significantly.
Theravance, a biopharmaceutical company, carries a Zacks Rank #3
(Hold). Biopharma companies that currently look more attractive
Alexion Pharmaceuticals, Inc.
). While Jazz Pharma is a Zacks Rank #1 (Strong Buy) stock,
Cytokinetics and Alexion Pharma carry a Zacks Rank #2 (Buy).
ALEXION PHARMA (ALXN): Free Stock Analysis
CYTOKINETCS INC (CYTK): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
THERAVANCE INC (THRX): Free Stock Analysis
To read this article on Zacks.com click here.